CDK1 and cancer: In consonance with this observation, we found that patients whose tumors lacked anti-249T-P or anti-CDK1 staining had longer overall survival (OS; p = 0.048 and 0.036, respectively) than patients whose cancers showed with anti-249T-P staining (Fig. 2q, r).